Most strategic transactions don’t fail at signing. They fail at execution.
Acquisitions, partnerships, and exits often look flawless on paper — yet value erodes once governance shifts, incentives misalign, and decision-making slows down. These risks are usually visible before the deal is signed, but rarely addressed openly.
This roundtable brings together startup CEOs nearing a strategic transaction and experienced M&A professionals from pharma, diagnostics, and digital health to have an honest, execution-first conversation.
We will examine where deals actually break, what founders tend to underestimate about power and control shifts, and what acquirers already know will be hard to execute — but sign anyway.
We will have a candid exchange on how to prevent value destruction between signing and integration.
Hosted by Valérie Hepp, founder of Breakline Resolution, specialising in execution risk, high-stakes negotiation, and conflict resolution in strategic life-sciences transactions.